North River (NRRP) Quote

OK, Begin !!

GO ZHUD$

Speaking of Collaborators:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175104205

https://investorshub.advfn.com/uimage/uploads/2024/9/23/xxvcoIMG_0264.jpeg

I only worry if I turn the key and it doesn't start LOL.... My Vette I have to have a trickle charge on it all winter long or with all the electrical gadgets if has like an onboard computer, will run down the battery easy in a 3 weeks. That's why yo hardly see a newer Vette in the parking garage at

v .......legacy of suing the big guys.....and/or os............was it AI?
sharepoint.........we assume it's sharing/collaborating with another user of human variety, but what if it's a machine and ai response........it just needed a generative response interface to be the 'hal' version humans

Sharing the same misinformation about IFUS over and over isn't helping anyone Boo Boo.

Perhaps October will be a better month for small caps...

$XXII 22nd Century Updates Strategic Growth Initiatives for VLN Low Nicotine Tobacco Products.
https://finance.yahoo.com/news/22nd-century-updates-strategic-growth-115500015.html

$CLNV $PHBI $CBDW $BOTY $AHRO $AGBA $SPZI $GTVH $PHBI $IFUS $IGEX $ASII $RJR $MO

$XXII 22nd Century Updates Strategic Growth Initiatives for VLN Low Nicotine Tobacco Products.
https://finance.yahoo.com/news/22nd-century-updates-strategic-growth-115500015.html

$CLNV $PHBI $CBDW $BOTY $AHRO $AGBA $SPZI $GTVH $PHBI $IFUS $IGEX $ASII $RJR $MO

OK Begin

GO AZRH$

keep in mind KAVL are only getting 10% in the merger deal
https://x.com/READY_2_PROFIT/status/1838207206056935682

Hi NASDAQ2020, Purdue sued Accord first and sued Elite second. This saved Elite a lot of legal expenses, but indicates that Purdue saw Accord as the more imminent threat. My guess is they get to market ahead of Elite. It is still a needle mover if Elite crosses the line second.

https://www.aboutamazon.com/news/operations/how-amazon-deploys-robots-in-its-operations-facilities

All these robots need power.

https://assets.aboutamazon.com/dims4/default/9eac0d9/2147483647/strip/true/crop/2000x1125+0+0/resize/767x431!/quality/90/?url=https%3A%2F%2Fa

Pathetic. You are the largest shareholder of the company, you control a group that owns more than 50% of erhe shares, and the only information you can dig up comes from linkedin, a switchboard operator, and gossip at a women's oil conference. Sad that you are forced to cling to years old, heavily

Hey Zhodar,

Good to hear you are still around. And glad to hear that Weasel and I have helped you learn along the way. Hopefully you are not too far in the hole on this one and maybe took advantage of trading opportunities along the way.

Anyway agree with what Weasel

So $1.05 price target near term?

Not sure I'd trust the lumpy pillow guy with anything.

AILE.....TRNR......TGL...........................https://stockcharts.com/h-sc/ui?s=TGL&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=TRNR&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=AILE&p=D&yr=0&mn=2&dy=12&id=p84071410134

$XXII Huge News Out ~ International Expansion!
Link: https://finance.yahoo.com/news/22nd-century-announces-branded-products-120000365.html

https://investorshub.advfn.com/uimage/uploads/2024/9/23/rsxjnxxii-news.png

Morning rant if you missed: https://www.optionmillionaires.com/jb-morning-rant-september-3rd-2024-2/

New week ahead, can we break past 0.015's? Let's see some juicy news/filings!

Morning y'all

Yes on three accounts

Neither, the global cabal is running the country.

This is good news!

I believe I read on this board that Kidrin is no longer taking a salary.

From 10Q ……Salaries and related increased by $21,364 to $129,298 from $107,934 for the six months ended June 30, 2024 and 2023, respectively. The CEO’s salary is based on the terms of his 2018 employment agreem

It doesn't matter that most of the A/S has been used as any further acquisitions will be made with Preferred Z shares - as stated in the notes.

Something like this is best case scenario for L, IMO. Read all the comments.


>>Prof John Gallacher, Director of Dementia Research UK and University of Oxford.

“Whatever your view on the decision taken by MHRA and NICE, the key take-away is that Lecanemab has